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OBJECTIVES This study was designed to determine whether reductions in morning systolic blood pressure
(BP) elicited by treatment of moderate to severe obstructive sleep apnea (OSA) in heart
failure (HF) patients are associated with a reduction in sympathetic vasoconstrictor tone.
BACKGROUND Daytime muscle sympathetic nerve activity (MSNA) is elevated in HF patients with
coexisting OSA. In our recent randomized trial in HF, abolition of OSA by continuous
positive airway pressure (CPAP) increased left ventricular ejection fraction (LVEF) and
lowered morning systolic BP.
METHODS Muscle sympathetic nerve activity, BP, and heart rate (HR) of medically treated HF patients
(EF45%) and OSA (apnea-hypopnea index20/h of sleep) were recorded on the morning
after overnight polysomnography, and again one month after patients were randomly
allocated nocturnal CPAP treatment or no CPAP (control).
RESULTS In nine control patients, there were no significant changes in the severity of OSA, MSNA,
systolic BP, or HR. In contrast, in the 8 CPAP-treated patients, OSA was attenuated, and
there were significant reductions in daytime MSNA (from 58  4 bursts/min to 48  5
bursts/min; 84  4 bursts/100 heart beats to 72  5 bursts/100 heart beats; p  0.001 and
p  0.003, respectively), systolic BP (from 135  5 mm Hg to 120  6 mm Hg, p  0.03),
and HR (from 69  2 min1 to 66  2 min1; p  0.013).
CONCLUSIONS Treatment of coexisting OSA by CPAP in HF patients lowers daytime MSNA, systolic BP,
and HR. Inhibition of increased central sympathetic vasoconstrictor outflow is one mecha-
nism by which nocturnal CPAP reduces awake BP in HF patients with moderate to severe
OSA. (J Am Coll Cardiol 2005;45:2008–11) © 2005 by the American College of
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.12.080Cardiology Foundation
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abstructive sleep apnea (OSA), with 15 apneic or hypo-
neic events per hour, is present in 4% to 9% of the adult
orth American population aged 30 to 60, but its reported
revalence in heart failure (HF) patients with impaired left
See page 2012
entricular (LV) systolic function is substantially higher—
etween 11% and 37% (1). Heart failure is a condition in
hich sympathetic activation in the awake state has been
inked to premature mortality and sudden death (2). Ob-
tructive sleep apnea-induced apnea, hypoxia, hypercapnia,
nd arousal trigger surges in central sympathetic vasocon-
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004, accepted December 6, 2004.trictor outflow, peripheral resistance, and blood pressure
BP) during sleep (1). Individuals with normal LV systolic
unction and OSA exhibit increased muscle sympathetic
erve activity (MSNA) even while awake (3,4). This carryover
ffect is also evident in HF patients, in whom coexisting OSA
s associated with higher daytime MSNA (5).
In our recent randomized trial involving 24 HF patients
mean LV ejection fraction [LVEF] 27%) with coexisting
SA, 1 month of therapy with nocturnal continuous
ositive airway pressure (CPAP) caused a increase in day-
ime LVEF and a significant reduction in morning systolic
P (6). We considered attenuation of daytime sympathetic
asoconstrictor discharge a likely mechanism for this fall in
P. We therefore recruited additional patients to test the
ypothesis that abolition of coexisting OSA in HF by
PAP would lower daytime MSNA.
ETHODS
ubjects. Following ethics board approval and informed
onsent, we studied men and women with 1) HF of 6
onths duration; 2) LVEF 45% (radionuclide angiogra-
hy); 3) 3 months of stable optimal drug therapy at
ighest tolerated dose; 4) moderate to severe OSA (20
pneas and hypopneas/h of sleep) with 50% of events
bstructive (1,7); and 5) sinus rhythm. Exclusion criteria
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June 21, 2005:2008–11 CPAP Reduces MSNA in Heart Failure With OSAncluded: 1) primary valvular heart disease; 2) cardiac
acing; and 3) unstable angina, myocardial infarction, or
ardiac surgery within three months (6).
olysomnography. All subjects underwent a second base-
ine overnight polysomnographic study, with sleep stages,
pneas, hypopneas, and arousals defined and scored as
reviously described (6,7). Oxyhemoglobin saturation
SaO2) was monitored by pulse oximetry. The apnea-
ypopnea index (AHI) was calculated as the frequency of
pneas and hypopneas/h of sleep.
easurement of HR, BP, and MSNA. The next morn-
ng, the electrocardiogram, BP (digital photoplethysmogra-
hy; Finapres 2300, Ohmeda, Englewood, Colorado) and
eroneal MSNA were recorded over 15 min, with subjects
wake, resting quietly supine, and breathing without apnea,
s confirmed by respiratory inductance plethysmography.
uscle sympathetic nerve activity was expressed as burst
requency (bursts/min) and burst incidence (bursts/100
ardiac cycles) (8,9).
rotocol. Subjects were allocated randomly to either a
ontrol group (optimal HF drug therapy) or to a group that,
n addition, received CPAP. The night after the baseline
leep study, the latter subjects underwent overnight CPAP
itration, during which pressure was adjusted to abolish
pneas and hypopneas or to the highest tolerated level. They
ere then provided a metered CPAP machine to document
ours of use and were instructed to apply this for 6 h
ightly. After one month the sleep study and the awake
tudy were repeated.
tatistics. All data were acquired and analyzed by investiga-
ors blinded to the sequence of studies and treatment. Data are
xpressed as mean  SEM. Analyses were performed using
igmaStat 2.03 (SPSS Inc., Chicago, Illinois). Baseline char-
cteristics were compared by two-tailed unpaired t tests for
ontinuous variables and the Fisher exact test for nominal
ariables. Two-way repeated measures analyses of variance,
ollowed by Tukey’s test, were used to compare within- and
etween-group differences in variables obtained one month
part. A p value 0.05 was considered significant.
ESULTS
igh-quality MSNA data from both sessions were acquired
Abbreviations and Acronyms
AHI  apnea-hypopnea index
BP  blood pressure
CPAP  continuous positive airway pressure
HF  heart failure
HR  heart rate
LV  left ventricular
LVEF  left ventricular ejection fraction
MSNA  muscle sympathetic nerve activity
OSA  obstructive sleep apnea
SaO2  oxyhemoglobin saturationrom 17 subjects, 9 randomized to control and 8 to CPAP NTable 1). Groups were similar for age; body mass index;
VEF; AHI (80% of respiratory events were obstructive);
inimum SaO2; sleep structure; arousal frequency; and use
f digoxin (41%), diuretics (76%), angiotensin-converting
nzyme inhibitors (100%), and beta-receptor antagonists
59%).
Neither drug use nor body mass index changed signifi-
antly between the baseline and one-month studies. In
ontrol patients, there were no significant changes in total or
bstructive AHI, or any other polysomnographic variable.
n contrast, CPAP, at a pressure of 7.5 0.5 cm H2O (used
.0  0.6 h/night), reduced total AHI (from 40.4  7.9
vents/h to 8.8  1.5 events/h; p  0.001 within- and p 
.01 between-group interaction), obstructive AHI (from
3.3  4.5 events/h to 4.2  1.0 events/h; p  0.001
ithin- and p  0.005 between-group interaction), and
rousal frequency (from 32.1  8.7/h to 14.3  3.5/h; p 
.025), and increased minimum SaO2 during sleep (90.8 
.5% vs. 78.4  4.6%; p  0.05).
In the control group, hemodynamic and microneuro-
raphic variables were similar on the two study days (Table
). In CPAP-treated subjects, awake systolic BP fell by 15.4
4.9 mm Hg (p  0.015; p  0.04 for the between-group
omparison), as did HR (p  0.013; p  0.004 for
etween-group comparison). In contrast with control pa-
ients, there were significant reductions in MSNA burst
requency in all subjects (p  0.001; p  0.009 for
etween-group comparison). The MSNA burst incidence
lso fell (p  0.003) after one month of CPAP treatment
Table 2, Figs. 1 and 2).
ISCUSSION
his is the first randomized trial to examine the impact of
reating OSA on MSNA. In those patients with coexisting
ystolic HF, treating OSA with nocturnal CPAP for one
onth caused significant reductions in morning MSNA,
ystolic BP, and HR. Remarkably, these cardiovascular
ffects of CPAP were observed on a background of medical
F therapy (including angiotensin-converting enzyme in-
able 1. Subject Characteristics
Control
Group
CPAP
Group
p
Value
umber of subjects 9 8
ge, yrs 52.2  4.1 55.0  2.0 0.57
ender, M:F 7:2 8:0 0.47
MI, kg/m2 31.3  1.6 29.9  1.5 0.54
ause of HF 1.00
ICM, n (%) 5 (55.6) 5 (62.3)
Non-ICM, n (%) 4 (44.4) 3 (37.5)
ypertension, n (%) 5 (55.6) 3 (37.5) 0.64
YHA functional class 1.00
II, n (%) 4 (44.4) 3 (37.5)
III, n (%) 5 (55.6) 5 (62.5)
VEF, % 28.6  3.0 32.1  3.8 0.48
MI  body mass index; CPAP  continuous positive airway pressure; HF  heart
ailure; ICM  ischemic cardiomyopathy; LVEF  left ventricular ejection fraction;
YHA  New York Heart Association.
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CPAP Reduces MSNA in Heart Failure With OSA June 21, 2005:2008–11ibition and beta-blockade) that should attenuate the im-
act of any additional intervention on BP or HR. Because
entricular systolic function is affected adversely by increases
n cardiac afterload (10,11), these decreases have important
herapeutic implications.
These findings also provide new insight into the contri-
ution of sympathetic vasoconstrictor tone to BP regulation
n HF patients with coexisting OSA. Muscle sympathetic
able 2. Hemodynamic and Microneurographic Variables
Control Group
Baseline 1-Month
R, min1 72.7  3.4 74.5  3.9
BP, mm Hg 141.2  9.8 145.7  9.1
BP, mm Hg 66.6  4.1 66.8  4.0
VEF, % 28.6  3.0 30.8  7.8
SNA, bursts/min 63  3 63  4
SNA, bursts/100 cc 87  2 85  4
p  0.005 for treatment time between-group interaction; †p  0.05; ††p  0.01.
cc  cardiac cycles; DBP  diastolic blood pressure; HR  heart rate; MSNA 
n Table 1.
igure 1. Baseline and one-month muscle sympathetic nerve activity
MSNA) and electro tracings from a control subject and a subject
andomized to continuous positive airway pressure (CPAP). ECG 
lectrocardiogram.
p
serve activity is increased in most patients with HF, in
hom it relates directly to resistance in the vascular bed
istal to the recording electrode (12). However, there is
onsiderable interindividual variation in sympathetic nerve
ring rates in patients with systolic HF that cannot be
xplained simply on the basis of reflex responses to their
ltered hemodynamics (2,8). One potential source of such
ariation is the additional sympatho-excitatory influence of
oexisting OSA. Upper airway obstruction not only acti-
ates the sympathetic nervous system of HF patients reflex-
vely by eliciting apnea, hypoxia, hypercapnia, a fall in
ardiac output, and arousal from sleep (1,9), but exposure to
rief episodes of intermittent hypoxia evokes sympathetic
ctivation and BP elevation that persist long after recovery
rom the hypoxic stimulus (13,14). Thus, recurrent obstruc-
ive apneas at night in HF patients could elicit sustained
ftereffects on MSNA and BP that carry-over into the
wake state. Consistent with this concept, in our series of
01 patients with HF, those with OSA had higher daytime
ystolic BP than those without, despite their receiving more
ntihypertensive therapy; systolic BP correlated directly
ith the AHI (15). We proposed that their higher awake
P was due in part to increased daytime sympathetic
CPAP Group
p Value Baseline 1-Month p Value
0.08 68.8  2.3 65.9  2.3 0.013*
0.47 134.9  5.2 119.5  5.5 0.03†
0.94 70.9  5.1 62.6  5.1 0.06
0.46 32.1  3.8 38.3  3.8 0.06
0.80 58  4 48  5 0.001††
0.39 84  4 72  5 0.003
le sympathetic nerve activity; SBP  systolic blood pressure. Other abbreviations as
igure 2. Individual values and means  SE for muscle sympathetic nerve
ctivity (MSNA) burst frequency at baseline and after one month in control
atients (left) and continuous positive airway pressure (CPAP)-treated
ubjects (right).
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June 21, 2005:2008–11 CPAP Reduces MSNA in Heart Failure With OSAasoconstrictor tone (5) that might be reduced if OSA were
reated with CPAP.
In HF patients, acute abolition of obstructive apnea
uring sleep with CPAP causes immediate reductions in
ystolic BP and HR (16). In subjects with OSA but without
F, long-term treatment with CPAP lowers awake systolic
P (17). In our recent randomized trial involving medically
reated HF patients with OSA, the addition of nocturnal
PAP increased mean daytime LVEF from 25% to 34%,
et at the same time lowered morning systolic BP by 10 
mmHg (6). The present study is an extension of that trial,
ith the objective of testing the new hypothesis that
bolition of obstructive apnea during sleep would abrogate
ts daytime sympatho-excitatory pressor aftereffects (5). Our
emonstration of reductions in MSNA, systolic BP, and
R after one month of treatment of OSA by CPAP are
onsistent with this hypothesis and indicate that inhibition
f sympathetic vasoconstrictor discharge is one mechanism
y which nocturnal CPAP lowers daytime systolic BP in
F patients with moderate to severe OSA.
A similar randomized trial detected an absolute increase
n daytime LVEF of 5% after 3 months of CPAP therapy,
ut no change in mean arterial BP (systolic BP was not
eported) (18). Importantly, these authors recruited subjects
ith milder OSA (AHI 5 events/h) and HF (LVEF
55%) and presumably less baseline sympathetic activation.
his cannot be confirmed, however, because neither MSNA
or daytime plasma norepinephrine were measured.
Four major risk factors for ventricular remodeling, myo-
yte loss, disease progression, and premature mortality in
atients with impaired LV systolic function and OSA are 1)
brupt increases in negative intrathoracic and LV transmu-
al pressures (i.e., afterload) and distending forces during
bstructive apneas, resulting in increased myocardial energy
equirements; 2) nocturnal hypoxia and oxidative stress; 3)
octurnal and daytime sympathetic activation; and 4) noc-
urnal and daytime hypertension. Treatment of HF patients
ith coexisting OSA by nocturnal CPAP addresses each of
hese risk factors and therefore has the potential to improve
V systolic function via several mechanisms. Compared
ith HF patients with normal breathing patterns during
leep, those with OSA are exposed to the adverse effects on
he failing heart and circulation of increased central sympa-
hetic outflow during sleep and when awake. By removing
his additional apnea-induced stimulus to sympathetically
ediated vasoconstriction, and thereby lowering systolic BP
hrough specific therapy of coexisting OSA, nocturnal
PAP might improve the prognosis of HF patients withoderate to severe OSA. This hypothesis merits specific
esting in a longer term outcome trial.
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